Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02888587 · ClinicalTrials.gov registry record

The Innervation of Human Gut Sensory Epithelial Cells

A clinical trial of Organoids, sponsored by Duke University.

Completed
Registry status
42
Enrollment target
1
Study location

NCT02888587: Completed study of Organoids, sponsored by Duke University.

NCT02888587 is a study of Organoids that has completed, run by Duke University. The registered enrollment target is 42 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02888587, a study of Organoids, has completed, sponsored by Duke University.

COMPLETED
Registry status
42 participants
Enrollment target
1
Study location

Study Summary

The study has two objectives: 1. To obtain endoscopic and colonoscopic biopsies to harvest and culture intestinal crypts from human tissue to produce organoids. These organoids will be used to study the biology of innervated sensory epithelial cells. 2. to collect subject data relating to clinical management and demographic characteristics of patients undergoing upper endoscopy or colonoscopy to learn the mechanisms behind visceral hypersensitivity, and neurodegenerative diseases that may arise in the gut.

Primary Outcome

Organoids are expected to contain enteroendocrine cells. We will use electrophysiology to measure the electrical excitability of these cells. In enteroendocrine cells from patients with a visceral hypersensitivity diagnosis is expected that cells will fire action potentials at a significantly lower threshold. These results will be correlated with RNA sequencing analysis to study the expression of sensory receptors in enteroendocrine cells.

Conditions Studied

Study Locations (1)

North Carolina

  • Duke Medical Center - Durham

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2017-09-05
Est. Completion 2022-12-01
Duke University

1,725 total trials

What the finished NCT02888587 record still lists

NCT02888587 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 42 participants, a relatively small participant target.

The record links to 1 condition, with Organoids appearing as the primary indexed condition, and to 0 interventions.

NCT02888587 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT02888587 about?

NCT02888587 is a clinical study titled "The Innervation of Human Gut Sensory Epithelial Cells". The study has two objectives: 1. To obtain endoscopic and colonoscopic biopsies to harvest and culture intestinal crypts from human tissue to produce organoids. These organoids will be used to study the biology of innervated sensory epithelial cells. 2. to collect subject data relating to clinical ...

What is the current status of trial NCT02888587?

This trial is currently completed. The enrollment target is 42 participants. The study started on 2017-09-05. Estimated completion is 2022-12-01.

What conditions does trial NCT02888587 study?

This clinical trial studies the following conditions: Organoids.

Who is sponsoring clinical trial NCT02888587?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02888587 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02852213 · 42 participants · Phase 1

    A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients

  • NCT03136146 · 42 participants · Phase 2

    Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

  • NCT03178149 · 42 participants · Phase 1

    A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

  • NCT03663530 · 42 participants · NA

    Circadian Misalignment and Energy Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02888587, the US trial registry maintained by the National Library of Medicine. NCT02888587 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.